Slide 1: Intimation to NSE under Regulation 30
Date: August 20, 2025 To, The Manager- Listing Department, National Stock Exchange of India Limited, Exchange Plaza, Plot No. C/1, Block-G, Bandra - Kurla Complex, Bandra (E), Mumbai - 400051 SYMBOL: REMUS Dear Sir/Madam, Sub.: Intimation under Regulations 30 of the Securities and Exchange Board of
Slide 2: Investor Presentation August 2025
InvestorPresentation August 2025 www.remuspharma.com
Slide 3: Snapshot
Snapshot 620+ registered products, Over 150 First-to-market products in FY25 Return Ratios 400+ products distributors globally niche therapies. RoE: 15.01% commercialized, 2000+ SKU’s RoCE: 15.69% across diverse therapeutic Net Debt to Equity: 0.05 segments Strong last-mile reach 745+ dossier ready-
Slide 4: Contents
1 Company Overview 2 Business Overview 3 Strategic Overview Contents 4 Industry Overview 5 Financial Overview
Slide 5: Company Overview
Remus=j= Company Overview
Slide 6: Company Overview
Company Overview • Remus Pharmaceuticals Limited, established in 2015, is one of the fastest growing pharmaceutical Revenues (INR Mn) companies. • Remus specializes in branding, marketing, and distribution of complex specialty and niche off patent 6,204 formulations in various countries. • The compa
Slide 7: Key Milestones
Key Milestones • Acquired Espee USA • LATAM Expansion: Deepened presence via incorporation in new countries and long- • Initiated presence in key international markets term alliances with local distributors. with focused product launches. • Created Relius brand for advance market development, specia
Slide 8: Experienced Board of Directors
Experienced Board of Directors Mr. Arpit Shah Mr. Swapnil Shah Ms. Roma Shah Ms. Anar Shah Managing Director Chairman & Non- Executive, Non- Independent Director Whole-time Director Non- Executive, Non- Independent Director Mr. Arpit Shah , an Engineer from Mr. Swapnil Shah holds a master’s degree M
Slide 9: Strong Global Presence
Strong Global Presence CIS & Eastern Europe 12 37 19 Azerbaijan Filed Under Process Registered Uzbekistan Georgia Bosnia & Commonwealth of Herzegovina Independent States - 68 Kosovo Total 2,000+ South East Asia - 225 111 107 7 Filed Under Registered Latin America – 1,596 Process Asia & South-East As
Slide 10: Business Overview
Remus=j= Business Overview
Slide 11: Business Value Chain
Business Value Chain Market Product Product Marketing & Research Indentification Registration Procurement Manufacturing Export Distribution • Track global • Focus on high- • Prepare dossiers • Global standard • We outsource ready- • B2B Export • Dedicated sales & therapy trends margin, off through i
Slide 12: Product Registration & Regulatory Roadmap
Product Registration & Regulatory Roadmap Step 01 Step 02 Step 03 Step 04 Step 05 Step 06 Step 07 Market & Product Technical Feasibility Formulation Data Compilation Regulatory Review Submission to Commercial Identification & Partner Alignment Development for Dossier & Compliance Check Health Author
Slide 13: Regulatory QC/QA
Regulatory QC/QA Expert Dossier Bioequivalence, Clinical, Dynamic Timely & Quality Regulatory Submission and Non-Clinical & Adaptive Strategic Assurance Affairs Team Excellence Research Team Assessment & Control A highly skilled team of Submitting 50+ Performing Dynamic and young Conducting up-to-da
Slide 14: B2B Business
B2B Business B2B Partner Driven Scalability Revenue (INR Mn) & Product Growth 748 • End-to-end regulatory & commercial solutions for global partners 619 • Fast-track entry into semi-regulated & emerging markets • In-house regulatory expertise ensuring swift market access • Low R&D risk, faster comme
Slide 15: B2C Business
B2C Business B2C Brand-Led Profitability Revenue (INR Mn) & Product Growth • Operates under Relius brand via Bolivia & Guatemala subsidiaries 34 • Strong last-mile reach through D2C + pharmacy channels • High safety & efficacy aligned with global standards • Building brand equity via trademark prote
Slide 16: Integrated Product Snapshot
Integrated Product Snapshot SKUs Registered Products Tablets Ointments, Injectables 973* Creams & Gels 534* 698 78* 594 436 334 275 Inhalers/ Syrups & Oral Suspensions Capsules (Hard Gel 2021 2022 2023 2024 2025 Nebulizer 48* & Soft Gel) 26* 221* Therapeutic-Wise Registrations (%) Antifungal 2% Anti
Slide 17: Our Story - Connecting with the Community
Our Story - Connecting with the Community Brand Awareness Conference Farmacorp Conference and St. Agustin's Pharmacy with 5 5 + doctors and pharmacy Training Event - December 2 0 2 4 Chain Training - J a n 2 0 2 5 representatives - O c to b er 2 0 2 4 Awareness Event for gynecologists, Training for
Slide 18: One of the world's largest pharmaceutical finished formulations specialty distributor
Among the world’s largest RLD distributors – Extensive global network and sourcing capabilities with an expertise in sourcing and supplying hard-to-get REMS, specialty, orphan, and biosimilar drugs. Advanced Supply Chain – Customized dashboards, trend analysis, and complete logistics support for glo
Slide 19: Strategic Overview
Remus=j= Strategic Overview
Slide 20: Differentiating Factors
Key Strengths Brand Excellence Future-Ready Portfolio Registering and trademarking our Comprehensive data on molecules going own brands, building a off-patent up to 2038 regional presence Swift Market Entry Global Tie-ups Developing recently off-patent products Strong strategies for MABs, for First
Slide 21: Growth Strategies
Growth Strategies Building strong 600+ B2C products Training field force New market Increase presence Expand presence in direct-to-consumer in development, for ethical, doctor- entries: in developed semi-regulated and (D2C) and Targeting 200+ B2C driven promotion Bosnia, Ethiopia, markets – organic
Slide 22: Industry Overview
Industry Overview Investor Presentation | 21
Slide 23: Global Pharmaceutical Market
Global Pharmaceutical Market Global Demand Drivers The Global Pharmaceutical formulations market was valued at USD $1,511 Bn in FY2025, up from USD $1,289 Bn in Increase in ageing population FY2022. It grew at a CAGR of approximately 5.4% Increasing prevalence of chronic diseases between FY2022 and
Slide 24: Indian Export Market
Indian Export Market India ranks Exports reach In FY24, exports stood India contributes Emerging markets such Pharma exports 3rd globally in 200+ countries, at INR 2.43 lakh crore ~20% of global as Latin America and expected to grow pharmaceutical with the US as (USD 27.82 billion); generic drug exp
Slide 25: Historical Financials
Remus=j= Historical Financials
Slide 26: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) FY24 FY25 Operational Revenue 2,129 6,204 Total Expenses 1,839 5,747 EBITDA 290 457 EBITDA Margins (%) 13.62% 7.37% Depreciation and Amortisation 11 19 Finance costs 5 15 Other Income 28 50 PBT 302 473 Tax 59 89 PAT 243 384 PAT Margins (%
Slide 27: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet ASSETS (INR Mn) FY24 FY25 EQUITY & LIABILITIES (INR Mn) FY24 FY25 Non-current assets Equity Share Capital 15 59 Reserve and Surplus 1,562 2,500 a)Property, Plant & Equipment and Intangible Assets - - Total Equity 1,577 2,529 i) Property, Plant & Equipment 21 47
Slide 28: Standalone Financial Highlights
Standalone Financial Highlights Revenue From Operation (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 260 199 792 210 639 32.86% 32.83% 166 25.98% 25.13% FY24 FY25 FY24 FY25 FY24 FY25 Net Debt to Equity (X) Trade Receivables Days ROCE* (%) & ROE* (%) 83 24.57% FY24 FY25
Slide 29: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue From Operation (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 6,204 457 384 290 243 2,129 13.62% 11.41% 7.37% 6.19% FY24 FY25 FY24 FY25 FY24 FY25 Net Debt to Equity (X) Working Capital Days ROCE* (%) & ROE* (%) 0.05 122 15.99% 1
Slide 30: Capital Market Data
Capital Market Data 1 YEAR SHARE PRICE MOVEMENT (UP TO 31st March 2025) 60% 50% 40% 30% 20% 10% 0% -10% -20% -30% Apr-24 May-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 REMUS NIFTY SMALLCAP 250 PRICE DATA (As on 31st March 2025) SHAREHOLDING PATTERN (As on 31st March 202
Slide 31: Disclaimer
Disclaimer Remus Pharmaceuticals Ltd. Disclaimer: The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This Presentation has been prepared by
Slide 32: Thank You
Registered Office 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli -Bopal Road, Ahmedabad, Gujarat, India, 380054 CIN ISIN L24232GJ2015PLC084536 INE0O5T01011 : REMUS Thank You